Shares of Sangamo Therapeutics climbed after the genomic medicine company entered a licensing agreement with Eli Lilly for STAC-BBB. The stock rose 31% to 81 cents on volume of 3.1 million shares in ...
The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback